Rapamycin treatment for Alzheimer's disease and related dementias: a pilot phase 1 clinical trial.

Mitzi M Gonzales, Valentina R Garbarino, Tiffany F Kautz, Xuemei Song, Marisa Lopez-Cruzan, Leslie Linehan, Candice E Van Skike, Gabriel A De Erausquin, Veronica Galvan, Miranda E Orr, Nicolas Musi, Yingxin He, Randall J Bateman, Chen-Pin Wang, Sudha Seshadri, Ellen Kraig, Dean Kellogg

Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. [email protected] Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. [email protected]. · pubmed

Paper

Abstract

Rapamycin has been shown to extend lifespan and acts on pathologies underlying Alzheimer's disease and related dementias in animal models. However, rapamycin's clinical application remains underexplored.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that rapamycin treatment may have potential benefits for Alzheimer's disease and related dementias. The research explores a therapeutic approach that targets underlying mechanisms of aging-related diseases, aligning with longevity research.

Author of this paper? Send a correction.